Prolonged inhibition of intratumoral mast cells enhances efficacy of low‐dose antiangiogenic therapy

Documenti analoghi

• Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC
  di: Eva Krieghoff‐Henning, et al.
  Pubblicazione: (2026)
• Leserbriefe – Correspondence
  di: André Heineke
  Pubblicazione: (2024)
• Enhancing cancer immunotherapy and antiangiogenic therapy by regulating gut microbes: Opportunities and challenges
  di: Jie Xu, et al.
  Pubblicazione: (2024)
• Safety and promising efficacy with enhanced CAR T‐cell therapy for lymphoma
  di: Mary Beth Nierengarten
  Pubblicazione: (2025)
• A new infinite class of $6d$, $\mathcal{N}=(1,0)$ supergravities
  di: Loges, Gregory J.
  Pubblicazione: (2024)